<DOC>
	<DOCNO>NCT01273142</DOCNO>
	<brief_summary>The purpose study demonstrate difference frequency level liver function disturbance patient efavirenz base ART , patient nevirapine base ART HBV HCV co-infected patient , ( and/or patient abnormal liver function prior ART ) , China . Liver function test measure baseline follow-up .</brief_summary>
	<brief_title>Compare Safety Efavirenz Nevirapine Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment , and/or Hepatitis B Hepatitis C Co-infection</brief_title>
	<detailed_description>The introduction highly active antiretroviral therapy ( HAART ) lead significant reduction AIDS-related morbidity mortality . However , frequent occurrence chronic hepatitis progress toward cirrhosis and/or hepatocarcinoma recognize increase contributor death HIV-infected patient since early HAART era In China among estimate 700,000 people live HIV China 20061 , percentage HIV/HCV co-infected patient high 56.9 % 2 . For reason , HAART scrupulous attention pay patient ' liver function . At present , price consideration , NNRTI HIV drug use antiretroviral therapy China nevirapine , may lead high potential risk liver function disturbance clinical practice efavirenz4-5.Roberto Manfredi colleagues3found NVP treat group , patient show least 2-fold increase transaminase versus baseline hepotoxicity index , EFV group , number patient hepotoxicity show reduction , Also study , time reach transaminase peak value shorter NVP group , also demonstrate liver toxicity side effect NVP group . Recently data also show unusually high incidence liver function disturbance patient HIV antiretroviral therapy China6 . Therefore evaluate frequency risk patient hepatotoxicity cause different HAART regimens HBV-/HCV- co-infected HIV patient necessary provide evidence therapy HAART treatment use China .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>( Patients must meet follow criterion enter study . ) Patients must &gt; 18years age &lt; 60 year age Patients must antiretroviral naive HIV1 RNA levelâ‰¥500 copies/ml Patients AST ALT &gt; 2x upper limit normal , TBIL &gt; 1.5x upper limit normal CD4 count &lt; 250 female patient &lt; 350 male patient entry Hemoglobin content &gt; 90g/L Neutrophil cell count &gt; 0.75 x 109/L Patients must willing accept Exclusion criterion : ( Patients meet one follow criterion enrol study . ) Patients allergy contraindication select ARV regimen . AST ALT &gt; 5x upper limit normal TBIL &gt; 2.5 x upper limit normal TB coinfection coinfection Pregnant breastfeed woman Intravenous drug user Patient 's education level would interfere medical , adherence withdrawal symptom evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Human Immunodeficiency Virus , liver toxicity , hapatitis co-infection</keyword>
</DOC>